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Abstract
BACKGROUND/OBJECTIVES—Determining long-term trends in tumor biomarker expression 
is essential for understanding aspects of tumor biology amenable to change. Limiting the 
availability of such data, currently used assays for biomarkers are relatively new. For example, 
assays for the estrogen receptor (ER), which are the oldest, extend back only to the 1970s.
METHODS—To extend scant knowledge about the feasibility of obtaining long-term data on 
tumor biomarkers, we randomly selected 60 breast cancer cases (10 per decade) diagnosed 
between 1947–2009 among women members of the Kaiser Permanente Northern California health 
plan to obtain and analyze their formalin-fixed paraffin-embedded (FFPE) tumor specimens. For 
each tumor specimen, we created duplicate tissue microarrays for analysis.
RESULTS—We located tumor blocks and pathology reports for 50 of the 60 cases (83%), from 
which we randomly sampled 5 cases per decade for biomarker analysis (n = 30). All 30 cases 
displayed excellent morphology and exhibited biomarkers compatible with histologic type and 
grade. Test–retest reliability was also excellent: 100% for ER; 97% for human epidermal growth 
factor receptor 2 and epidermal growth factor receptor; 93% for progesterone receptor and 
cytokeratin 5/6; and 90% for Ki67 and molecular phenotype; the kappa statistic was excellent 
(>0.9) for 4 of the 7 biomarkers, strong (0.6–0.8) for 2, and fair for only 1 (owing to low 
prevalence).
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CONCLUSIONS—These results indicate immunostaining for biomarkers commonly used to 
evaluate breast cancer biology and assign surrogate molecular phenotypes can reliably be 
employed on archival FFPE specimens up to 60 years old.
INTRODUCTION
Determining long-term trends in tumor biomarkers is crucial for understanding what aspects 
of tumor biology are amenable to change. Evidence of long-term trends critically 
complements cross-sectional comparisons, across geographical regions or social groups, 
because only long-term data can detect the impact of changing exogenous exposures.1 For 
example, the recent rise and fall in breast cancer incidence in many countries, linked to the 
rise and fall of postmenopausal hormone therapy use2–9 was paralleled by a rise and fall in 
the incidence of estrogen receptor positive (ER+) tumors.3,4 Of note, although breast cancers 
tumors are generally more often ER+ among US white compared with black women,10 the 
US white/black odds ratio for ER+ breast tumors nevertheless exhibited a parallel rise and 
fall during this same time period, a pattern likely attributable to changes in hormone therapy 
use.11
Scant knowledge, however, exists about the feasibility of locating and analyzing decades 
old, population-based archival formalin-fixed paraffin-embedded (FFPE) tumor specimens. 
Contributing to the lack of such historical data is the relatively recent development of most 
currently used assays: in the case of breast cancer, for example, one of the first such assays, 
for ER, became available only in the 1970s,12 and characterization of molecular phenotypes 
is an innovation of the 21st century CE.13 We accordingly conducted a novel feasibility 
study, including assessment of test–retest reliability, for a series of breast cancer cases 
spanning 6 decades (1947–2009). Favorable results would enhance interpretation of prior 
studies that have employed biomarker immunostains on old FFPE specimens, e.g., 30–40 
years old when analyzed,14,15 as well as encourage new research.
MATERIALS AND METHODS
For our study, we analyzed FFPE specimens obtained from women diagnosed with invasive 
breast cancer who were members of Kaiser Permanente, Northern California (KPNC; 
institutional review board approval: Harvard School of Public Health/#CR-20929–02; 
KPNC/#CN-13LHabe-03-H). KPNC is an integrated healthcare delivery system established 
in the 1940s16 and whose cancer registry dates back to 1947.17 Since its inception as a 
health plan for workers employed in World War II shipyards, KPNC’s membership has 
ranged from working class to professional and has mirrored the well-known diversity of the 
San Francisco Bay Area and Central Valley, comprised of white, black, Hispanic, Asian and 
Pacific Islander, and American Indian populations.17,18
Among the 60,904 breast cancer cases diagnosed between 1947 and 2009, 7,150 met our 
feasibility study’s eligibility criteria: 50–64 years old at diagnosis and invasive tumor ≥ 1 
cm. We randomly selected 10 eligible cases per each of the 6 time periods (hereafter 
referred to as decades: 1947–1959; 1960–1969;…; 2000–2009), and used information 
available as of 1987 to restrict sampling to cases with lymph node positive tumors. Our 
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rationale was to maximize the chance that biomarkers would be positive or credibly 
negative, given that advanced cases are more likely to be positive for human epidermal 
growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), high Ki67, 
ER−, and PR−.13,19 Thus, had the specimens included only early stage cancer, it would be 
less clear if negative test results could be interpreted as truly negative—versus falsely 
negative—because the assay was not sensitive to biomarker expression in the older 
specimens. Among the 50 cases located with eligible blocks containing tumor (as described 
below), and in accord with our a priori power calculations, we selected a random sample of 
5 cases per decade (total n = 30) for biomarker immunohistochemical analysis.
To conduct the assays, we first created tissue microarrays (TMAs) in duplicate, each 
employing 3, 0.6-mm cores per specimen. We assessed antigen preservation by using a 
cytokeratin (CK) “cocktail” immunostain (consisting of antibodies AE1/AE3 and Cam5.2, 
which together recognize a broad spectrum of CKs), and also performed immunostains for 
biomarkers routinely used to assess breast cancer biology and assign molecular phenotype 
based on surrogate markers13,19–22: ER, progesterone receptor (PR), HER2, CK 5/6, EGFR, 
and Ki67. The Ki67 stains were quantitated by computer-assisted image analysis;23 for each 
case, the score equaled the average percentage of positive cells per core. Review of the 
biomarkers was blinded to tumor histologic type and grade, and review of each set of TMA 
results was independent and blinded to the other. For each TMA, if a tumor marker was 
scored as positive for 1 or more cores, it received an overall rating of positive for that 
marker.
RESULTS
Among the random sample of 60 selected cases, we located pathology reports for 55 cases 
(92%), of which 50 (83% of the 60) had blocks that contained tumor tissue. Among the 
random sample of 5 cases per decade selected from these 50 cases, notably all 30 cases 
(100%) displayed excellent morphology and the CK cocktail staining results (Table 1) 
indicated antigen integrity was preserved for all but 2 of the cases (1 from the 1950s, 1 from 
the 1960s). Test–retest reliability was likewise excellent (Table 1): 100% for ER, 97% for 
HER2 and EGFR, 93% for PR and CK 5/6, and 90% for Ki67 (scored as < 14% vs. ≥ 
14%19). The kappa statistic (taking into account chance agreement;24 Table 1) was excellent 
(>0.9) for 4 of the 7 biomarkers, moderate-to-strong (0.6–0.8) for 2, and fair for 1 (0.346 for 
Ki67 as a dichotomous variable). On the basis of the biomarker results, concordance for 
molecular phenotype was 90% (kappa >0.7): classification of 15 cases was concordant for 
Luminal A, 3 for Luminal B, 3 for basal-like, 3 for HER2, and 2 for “unclassified”; only 3 
cases were discordant for classification as either Luminal A or B.
Assay results indicated that ~ 80% of tumors were ER+ (i.e., 80% for all decades except for 
the 1960s, for which 3/5 (60%) of the cases were ER+), all ER− tumors were grade 3, and 
virtually all ER+ tumors were grade 1 or grade 2. For PR, 60% of tumors were PR+ and all 
but one of the PR− tumors was grade 3 (the exception was grade 1). In addition, most tumors 
were negative for: HER2 (60–80% negative); CK 5/6 (87% negative); and EGFR (93% 
negative); Ki67 was < 14% for 86–90% of the cases.
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DISCUSSION
Considered together, our findings provide promising evidence for investigators seeking to 
conduct analyses of historical trends in tumor characteristics. First, perhaps unique to 
KPNC, we were able to locate pathology reports and informative tumor blocks for 83% of 
cases diagnosed between 1947 and 2009, with no discernible difference in specimen 
retrieval by decade. Second, more generalizably, we demonstrated that, among a random 
sample of breast cancer tumor specimens spanning this time period, current immunostaining 
methods for biomarkers commonly used to evaluate breast cancer biology and assign 
molecular subtype13,19–22 yielded plausible results for both old and recent specimens,13,19 
with excellent test–retest reliability. Of note, the lower test–retest reliability (93%) observed 
for both PR and CK 5/6 is consistent with prior studies indicating that expression of these 
biomarkers may demonstrate intratumor heterogeneity,21,22 regardless of the assay used. 
The high concordance (90%) but low kappa (0.346) for Ki67 reflects the low prevalence of 
high values.24
In summary, our study provides novel evidence that current immunostain techniques can 
feasibly and reliably be used on old FFPE specimens, dating back 60 years. It accordingly 
suggests that prior14,15 and future studies employing immunostains to characterize long-term 
trends in tumor biomarker expression at the population level can yield credible results.
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